Allogene Therapeutics, Inc.
ALLO- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001737287
In the last 90 days, Allogene Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 209 institutions reported holding it in 13F filings for Q2 2026, worth $652.0M in total; no superinvestor holds it.
13F holders, Q1 2026
Institutional positions in Allogene Therapeutics, Inc. as of Mar 31, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 209
- +39 vs. Q4 2025
- Shares held
- 184.2M
- +30.8M (+20.1%) vs. Q4 2025
- Total value
- $444.7M
- +$234.7M (+111.7%) vs. Q4 2025
- New holders
- 51
- 80 more added
- Sold out
- 12
- 40 more reduced
2 institutions that held it in Q4 2025 haven't filed for Q1 2026 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ALLO on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 209 | $652.0M |
| Q1 2026 | 209 | $444.7M |
| Q4 2025 | 172 | $222.7M |
| Q3 2025 | 170 | $201.0M |
| Q2 2025 | 158 | $207.9M |
| Q1 2025 | 171 | $288.5M |
| Q4 2024 | 174 | $401.9M |
| Q3 2024 | 156 | $460.4M |
| Q2 2024 | 175 | $385.1M |
| Q1 2024 | 161 | $586.0M |
| Q4 2023 | 170 | $392.4M |
| Q3 2023 | 155 | $413.3M |
| Q2 2023 | 171 | $662.9M |
| Q1 2023 | 176 | $582.3M |
| Q4 2022 | 168 | $700.9M |
| Q3 2022 | 192 | $1.15B |
| Q2 2022 | 161 | $1.15B |
| Q1 2022 | 180 | $836.7M |
| Q4 2021 | 177 | $1.28B |
| Q3 2021 | 169 | $2.26B |
| Q2 2021 | 182 | $2.25B |
| Q1 2021 | 169 | $3.12B |
Institutions, Q1 2026
Shares, value and share of portfolio for each institution holding Allogene Therapeutics, Inc.; share changes are against Q4 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Two Sigma Investments, LP | 5,375,456 | $13.1M | 0.01% | +1,952,015+57.0% | Added |
| Price T Rowe Associates Inc | 5,380,902 | $13.1M | 0.00% | +2,171,627+67.7% | Added |
| Citadel Advisors LLC | 6,793,620 | $16.6M | 0.01% | −5,317,800−43.9% | Reduced |
| Vanguard Capital Management LLC | 6,921,350 | $16.9M | 0.00% | +6,921,350 | New |
| Primecap Management Co | 8,379,840 | $20.4M | 0.02% | +240,000+2.9% | Added |
| State Street Corp | 8,660,306 | $21.1M | 0.00% | +5,898,906+213.6% | Added |
| TPG GP A, LLC | 18,716,306 | $45.7M | 1.24% | 00.0% | Unchanged |
| BlackRock, Inc. | 19,091,095 | $46.6M | 0.00% | +1,415,066+8.0% | Added |
| Pfizer Inc | 22,032,040 | $49.8M | 20.85% | 00.0% | Unchanged |
| Two Sigma Advisers, LP | 0 | $0 | 0.00% | −2,890,200−100.0% | Sold out |
| Kalehua Capital Management LLC | 0 | $0 | 0.00% | −2,546,129−100.0% | Sold out |
| Zacks Investment Management | 0 | $0 | 0.00% | −192,731−100.0% | Sold out |
| Aquatic Capital Management LLC | 0 | $0 | 0.00% | −51,894−100.0% | Sold out |
| Canada Pension Plan Investment Board | 0 | $0 | 0.00% | −38,200−100.0% | Sold out |
| Sagewood Asset Management LP | 0 | $0 | 0.00% | −16,625−100.0% | Sold out |
| Aigen Investment Management, LP | 0 | $0 | 0.00% | −15,416−100.0% | Sold out |
| StoneX Group Inc. | 0 | $0 | 0.00% | −14,867−100.0% | Sold out |
| Two Sigma Securities, LLC | 0 | $0 | 0.00% | −12,230−100.0% | Sold out |
| Cetera Investment Advisers | 0 | $0 | 0.00% | −10,207−100.0% | Sold out |
| Amalgamated Bank | 0 | $0 | 0.00% | −4,833−100.0% | Sold out |
| Daiwa Securities Group Inc. | 0 | $0 | 0.00% | −535−100.0% | Sold out |
| Vanguard Group Inc | – | – | – | – | Not filed |
| CIBC World Markets Corp | – | – | – | – | Not filed |